NCT02475681: A trial that was reported late by Acerta Pharma BV
This trial has reported, although it was 20 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02475681 |
|---|---|
| Title | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 26, 2015 |
| Completion date | Feb. 8, 2019 |
| Required reporting date | Feb. 8, 2020, midnight |
| Actual reporting date | Feb. 28, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 20 |